FOXM1: From cancer initiation to progression and treatment
The Forkhead box protein M1 (FOXM1) transcription factor is a regulator of myriad biological
processes, including cell proliferation, cell cycle progression, cell differentiation, DNA …
processes, including cell proliferation, cell cycle progression, cell differentiation, DNA …
FoxM1: a master regulator of tumor metastasis
P Raychaudhuri, HJ Park - Cancer research, 2011 - AACR
The FoxM1 transcription factor gene is overexpressed in cancer. Its expression is stimulated
by oncogenic signaling pathways and reactive oxygen species. It is also a target of …
by oncogenic signaling pathways and reactive oxygen species. It is also a target of …
Lysyl oxidase, extracellular matrix remodeling and cancer metastasis
Q Xiao, G Ge - Cancer microenvironment, 2012 - Springer
Lysyl oxidase (LOX) family oxidases, LOX and LOXL1-4, oxidize lysine residues in
collagens and elastin, resulting in the covalent crosslinking and stabilization of these …
collagens and elastin, resulting in the covalent crosslinking and stabilization of these …
Forkhead transcription factors in health and disease
L Herman, AL Todeschini, RA Veitia - Trends in Genetics, 2021 - cell.com
Forkhead box (FOX) proteins belong to an evolutionarily conserved family of transcription
factors that has evolved by gene/genome duplication. FOX family members have undergone …
factors that has evolved by gene/genome duplication. FOX family members have undergone …
Lysyl oxidase and the tumor microenvironment
The lysyl oxidase (LOX) family of oxidases contains a group of extracellular copper-
dependent enzymes that catalyze the cross-linking of collagen and elastin by oxidation, thus …
dependent enzymes that catalyze the cross-linking of collagen and elastin by oxidation, thus …
FOX (M1) news—it is cancer
M Halasi, AL Gartel - Molecular cancer therapeutics, 2013 - AACR
FOXM1 is an oncogenic transcription factor of the Forkhead family and it has a well-defined
role in cell proliferation and cell-cycle progression. Expression of FOXM1 is excluded in …
role in cell proliferation and cell-cycle progression. Expression of FOXM1 is excluded in …
Forkhead box transcription factors: double-edged swords in cancer
M Castaneda, P Hollander, SA Mani - Cancer research, 2022 - AACR
A plethora of treatment options exist for cancer therapeutics, but many are limited by side
effects and either intrinsic or acquired resistance. The need for more effective targeted …
effects and either intrinsic or acquired resistance. The need for more effective targeted …
FOXM1: a multifunctional oncoprotein and emerging therapeutic target in ovarian cancer
Simple Summary Ovarian cancer is a lethal disease in women with a 10-year survival rate
of< 40% worldwide. A key molecular alteration in ovarian cancer is the aberrant …
of< 40% worldwide. A key molecular alteration in ovarian cancer is the aberrant …
Stathmin: a protein with many tasks. New biomarker and potential target in cancer
B Belletti, G Baldassarre - Expert opinion on therapeutic targets, 2011 - Taylor & Francis
Introduction: Stathmin is a microtubule-destabilizing phosphoprotein, firstly identified as the
downstream target of many signal transduction pathways. Several studies then indicated …
downstream target of many signal transduction pathways. Several studies then indicated …
EMT and oxidative stress: a bidirectional interplay affecting tumor malignancy
E Giannoni, M Parri, P Chiarugi - Antioxidants & redox signaling, 2012 - liebertpub.com
Significance: Epithelial–mesenchymal transition (EMT) is emerging as a driving force in
tumor progression, enabling cancer cells to evade their “homeland” and to colonize remote …
tumor progression, enabling cancer cells to evade their “homeland” and to colonize remote …